Stock Track | Kardigan Soars 5.44% in Intraday Trading on Successful Nasdaq IPO Debut

Stock Track

8 hours ago

Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.

The surge follows the company's successful upsized initial public offering, which raised $400 million by selling 25 million shares at $16 each, the top end of its marketed price range. The IPO reflects renewed investor enthusiasm for biotech offerings this year.

Kardigan is developing precision therapeutics for cardiovascular diseases, with three late-stage experimental therapies in its pipeline. The company plans to use the IPO proceeds to fund clinical development of these drugs and for general corporate purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1123422178"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123422178\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123422178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-19 00:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123422178","market":"sg","top_or_hot":-1,"title":"Stock Track | Kardigan Soars 5.44% in Intraday Trading on Successful Nasdaq IPO Debut","media":"Stock Track","content":"<p>Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.</p><p>The surge follows the company's successful upsized initial public offering, which raised $400 million by selling 25 million shares at $16 each, the top end of its marketed price range. The IPO reflects renewed investor enthusiasm for biotech offerings this year.</p><p>Kardigan is developing precision therapeutics for cardiovascular diseases, with three late-stage experimental therapies in its pipeline. The company plans to use the IPO proceeds to fund clinical development of these drugs and for general corporate purposes.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kardigan Soars 5.44% in Intraday Trading on Successful Nasdaq IPO Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kardigan Soars 5.44% in Intraday Trading on Successful Nasdaq IPO Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-19 00:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.</p><p>The surge follows the company's successful upsized initial public offering, which raised $400 million by selling 25 million shares at $16 each, the top end of its marketed price range. The IPO reflects renewed investor enthusiasm for biotech offerings this year.</p><p>Kardigan is developing precision therapeutics for cardiovascular diseases, with three late-stage experimental therapies in its pipeline. The company plans to use the IPO proceeds to fund clinical development of these drugs and for general corporate purposes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KARD","symbol_name":"Kardigan","start_time":0,"source_url":"","article_id":"1123422178","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123422178","pubTimestamp":1781800867,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.The surge follows the company's successful upsized initial public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KARD":"Kardigan"},"translate_title":"股票赛道|纳斯达克IPO首秀成功Kardigan盘中大涨5.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KARD":1},"content_text":"Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.The surge follows the company's successful upsized initial public offering, which raised $400 million by selling 25 million shares at $16 each, the top end of its marketed price range. The IPO reflects renewed investor enthusiasm for biotech offerings this year.Kardigan is developing precision therapeutics for cardiovascular diseases, with three late-stage experimental therapies in its pipeline. The company plans to use the IPO proceeds to fund clinical development of these drugs and for general corporate purposes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}